Antibody Engineering Toward Enhancement of Teplizumab Anti-CD3 Binding Affinity in Type 1 Diabetes Prevention and Treatment
نویسندگان
1 Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Department of lmmunology, Faculty of Medicine, Shahid sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
2 Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Department of lmmunology, Faculty of Medicine, Shahid sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
3 Department of Medical Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran. Department of Molecular Medicine,School of Advanced Technologies in Medicine,Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
4 Department of Medical Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran. Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
5 Department of Mechanical Engineering, Yazd University, Yazd, Iran.
6 Research Center for Health Technology Assessment and Medical Informatics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
doi
10.18502/ijdo.v17i2.18848چکیده
Objective: The monoclonal antibodies with CD3 target have the potential to change the progression of type 1 diabetes (T1D) and enhance the longevity of beta-cell function. The main objective of the study is antibody engineering toward Enhancement of Teplizumab Anti-CD3 Binding Affinity in T1D prevention and treatment. Materials and Methods: We ...
